The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and a few SPACs scheduled to raise at least $900 million. Russian e-commerce company Ozon Holdings (OZON) plans to raise $750 million at a $4.4...read more
Eleven IPOs and nine SPACs priced this past week, getting out ahead of the US election. Markets tumbled and volatility spiked, as several deals broke issue and three IPOs postponed. The diverse group had very mixed trading, and averaged a return of 9.9%. New...read more
SQZ Biotechnologies, a phase 1 biotech developing cell therapies for solid tumors and other indications, raised $71 million by offering 4.4 million shares at $16, the low end of the range of $16 to $18. The company is developing cell therapies for...read more
SQZ Biotechnologies, a Phase 1 biotech developing cell therapies for solid tumors and other indications, announced terms for its IPO on Monday.
The Watertown, MA-based company plans to raise $75 million by offering 4.4 million shares at a price range of $16...read more
US IPO Week Ahead: The IPO market takes a break during the shortened holiday week
The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and a few SPACs scheduled to raise at least $900 million. Russian e-commerce company Ozon Holdings (OZON) plans to raise $750 million at a $4.4...read more
US IPO Weekly Recap: Big fintechs fall as 11 IPOs squeeze in ahead of the election
Eleven IPOs and nine SPACs priced this past week, getting out ahead of the US election. Markets tumbled and volatility spiked, as several deals broke issue and three IPOs postponed. The diverse group had very mixed trading, and averaged a return of 9.9%. New...read more
Solid tumor biotech SQZ Biotechnologies prices $71 million IPO at $16, the low end of the range
SQZ Biotechnologies, a phase 1 biotech developing cell therapies for solid tumors and other indications, raised $71 million by offering 4.4 million shares at $16, the low end of the range of $16 to $18. The company is developing cell therapies for...read more
Solid tumor biotech SQZ Biotechnologies sets terms for $75 million IPO
SQZ Biotechnologies, a Phase 1 biotech developing cell therapies for solid tumors and other indications, announced terms for its IPO on Monday. The Watertown, MA-based company plans to raise $75 million by offering 4.4 million shares at a price range of $16...read more